Pharming Group is a biotechnology company that develops products for the treatment of unmet medical needs, including RUCONEST® for the treatment of angioedema attacks in patients with HAE. The company operates through two business segments: Recombinant proteins and DNage. PHGUF focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. For more information, visit the company’s Web site: http://www.pharming.com
Let us hear your thoughts below: